Point mutations are commonly observed as primary oncogenic events in neuroblastoma (F1174L, R1275Q) or as secondary resistance mutations emerging following ALK inhibitor therapy (G1202R, L1196M) [26,27], which reduce inhibitor binding efficiency via enhanced ATP affinity or conformational alterations [28]. This evidence concerns the gene ALK and neuroblastoma.